WebAlterome Therapeutics, Inc. is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. We are a team with expertise in... WebFount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to …
Did you know?
WebAug 8, 2024 · In 2016, Steve co-founded Fount Therapeutics, a sustainable drug discovery enterprise which gave rise to Kinnate Biopharma in 2024, a small molecule precision oncology company. WebFOUNT THERAPEUTICS, LLC is a Delaware Limited-Liability Company filed on December 27, 2016. The company's File Number is listed as 6254661 . The Registered Agent on …
WebGet directions, reviews and information for Fount Therapeutics in San Diego, CA. You can also find other Biotechnology Products & Services on MapQuest WebStephen Kaldor, Ph.D. has served on our board of directors since October 2015. Dr. Kaldor has over 25 years of experience in the biotech and pharmaceutical industries. He …
WebJun 22, 2024 · He also serves as Chief Executive Officer and a director of Fount Therapeutics, LLC, and as a strategic advisor for Fronthera US Pharmaceuticals LLC, both biotechnology companies. Dr. Kaldor … WebOct 19, 2024 · Consulting or Advisory Role: Novartis, Genentech, Pfizer, Spectrum Pharmaceuticals, bioTheranostics, Merck, Radius Pharma, Immunomedics, Roche, Radius Health, Innocrin Pharma, Sanofi, Puma Biotechnology, Daiichi Sankyo/AstraZeneca Research Funding: bioTheranostics Open Payments Link: …
WebFount Therapeutics LLC Board Member Jun-2016 to Oct-2024 Crown Bioscience, Inc Global Head Oncology R&D Strategy and External Innovations Jan-2016 to May-2016 Crown Bioscience Global Scientific Director, Translational Oncology Mar-2014 to Jun-2015 Samumed LLC Dates Employed Director, Discovery Biology Jul-2011 to Mar-2014
WebMay 27, 2024 · Fount Therapeutics Secures $22M Series A Financing. by Kinnate Biopharma Apr 11, 2024 News. Fount Therapeutics Secures $22M Series A Financing Fount Therapeutics secures $22 million Series A financing from Foresite Capital and Eshelman Ventures. The funds will establish multiple subsidiary R&D companies to … foulkstown feedsWeb4 Department Of Melanoma, Cancer Immunotherapy And Development Therapeutics, Istituto Nazionale Tumori IRCCS “G. Pascale", 80131 - Napoli/IT 5 Department Of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, 77030 … foulks ranch elementary schoolWebFeb 6, 2024 · Therefore, BRAF is an attractive therapeutic target for these patients. Three BRAF-mutant–specific kinase inhibitors, dabrafenib ( 8–10 ), vemurafenib ( 11, 12 ), and encorafenib ( 13 ), are currently approved for treatment of patients with melanoma with the BRAF V600E/K mutation. disable pop up blocker edge in mobileWebFount Therapeutics LLC headquarters is in San Diego, California. Fount Therapeutics LLC is in the sectors of: Biotech. To connect with Fount Therapeutics LLC's employee … disable pop up ads windows 11WebSearch Fount Therapeutics management & employees. Enter a name to find & verify an email >>>. Rocketreach finds email, phone & social media for 450M+ professionals. disable pop up blocker in ms edgeWebNov 2, 2024 · SAN DIEGO-- ( BUSINESS WIRE )-- Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of alteration-specific targeted therapies for the treatment of cancer, today... disable pop up and add blockersWebFount Therapeutics, LLC * 1 Principals See who the company's key decision makers are 1 Contacts Reach the right people with access to detailed contact information. 9 See similar companies for insight and prospecting. Start Your Free Trial foulk woods